Speaker Experience of Dr. Molnar-Kimber

I’ve given many lively presentations as a speaker on topics ranging from how to deal with arthritis flares naturally to AIDS, native landscaping and cancer.

I recently gave a talk on "Nutritional Deficiencies as a Predisposing Factor in Onset of Rheumatoid Arthritis and RA Flares" at the Harmonization in Traditional, Alternative and Complementary Medicine Symposium in Montreal on Aug 5, 2012.

I spoke recently on “6 common causes of arthritis flares and how to deal with them naturally” at local Arthritis Support Group in Lansdale, PA. If you’re interested in a similar topic, please fill out the convenient contact page.

I tailor the presentation / discussion to the age group and level of understanding of the group.

For kids groups, I can also plan an hands-on activity.

Invited Speaker for Scientific Seminars

In addition, I’ve been an invited speaker at many scientific meetings and universities such as these listed below:

University of Colorado at Denver, April, 1983. “Mechanism of Replication of a Hepatitis B-like virus in ducks”

New York Blood Center, May, 1988. “Distinctive properties of the envelope proteins of Hepatitis B virus as investigated using recombinant adenoviruses”

Fox Chase Cancer Center, June, 1989. “Recombinant Adenoviruses as expression vectors for Hepatitis B and HIV proteins, leading toward a vaccine”.

University of Maryland, July, 1989. “Recombinant Adenoviruses as expression vectors for Hepatitis B and HIV proteins, leading toward a vaccine”

Wyeth-Ayerst, Nov. 1991: “Rapamycin and Phosphodiesterase Inhibitors on the immune syste” Georgetown University, Oct. 28, 1993. “Rapamycin as a probe of the immune system” American Physiological Society, June 28, 1994. Effects of small molecules on cytokine production and responses.

International Congress on New Immunosuppressive Drugs, August, 1995. “Mechanism of Action of Rapamycin”

Fourth International Mesothelioma Conference, May, 1997. “Adenoviral based Gene Therapy for Patients with Localized Mesothelioma induced cellular and humoral immune responses”

Sixth International Conference on Gene Therapy of Cancer, Nov., 1996. “Administration of recombinant adenoviral based gene therapy intrapleurally induced a TH1 cellular immune response in mesothelioma patients”

University of Pennsylvania, Feb., 1998. “Immune Responses induced by Adenoviral mediated Gene therapy in Mesothelioma Patients” Seventh International Conference on Gene Therapy of Cancer, Nov., 1997. “Administration of recombinant adenoviral based gene therapy intrapleurally induced a TH1 cellular immune response in mesothelioma patients”

American Association of Cancer Research Meeting. April 1, 1998. “Oncolytic effect of HSV-1 ICP34.5 mutants in Lung cancer”

Mid Atlantic Immunobiology conference, May 16, 1998 “Intrapleural administration of Ad-based gene therapy induced TH1 like responses in humans” International Congress on Gene Therapy, April 16, 1999. “Cancer Gene Therapy using replication selective HSV-1 mutants” Merck and Co, May 7, 1999. “Viral-Based Cancer Therapy” American Society for Gene Therapy, June 10, 1999. “Humoral anti-tumor immune response induced in mesothelioma patients by intrapleural administration of recombinant adenoviral-based gene therapy”

ONYX Pharmaceuticals, Inc. July 9, 1999. “Viral-Based Cancer Therapy”

Univ. of Pennsylvania, July 20, 2000. “Oncolytic Therapy of Colorectal Carcinoma by Replication Selective Adenoviruses”

ONYX Pharmaceuticals, Inc., May 25, 2001. “Viruses as Cancer Therapy”

Fox Chase Cancer Center, Aug. 21, 2001. “Oncolytic Viruses: Promising Agents for Ovarian and Cervical Cancer” Eastern Virginia Medical School, Oct. 24, 2001. “Replication Selective Adenoviruses as Cancer Therapy”

Tenth International Conference on Gene Therapy of Cancer, Dec. 13, 2001. “Replication selective herpes simplex virus-1 mutant therapy of cervical cancer is enhanced by low dose radiation” Geron Corporation, Aug., 2002. “Oncolytic Viruses: Promising Therapy for Cancer”

Banff Conference on Oncolytic Viruses, Mar. 27, 2003. “Oncolytic HSV Therapy for Gynecologic Cancers”

Oral Presentations at Scientific Conferences

Scientists (even scientists with RA) submit abstracts or summaries of their research to meeting organizers. The program committee then selects some of the most interesting abstracts for presentation. These presentations are usually shorter than if you’re an invited speaker.

My abstract or abstracts from my laboratory were often selected by the program committee for oral presentation.

In many cases, I was the speaker. I then described the objective, methods of the study, the results and our conclusions to the meeting participants.

Molnar, K.L. and Sprent, J. (1978). Evidence that thymus derived cell primary responses to Mls determinants is not under MHC gene control. Fed. Prod. 37: 1370. (oral)

Molnar, K.L. and Sprent, J. (1979). Thymus derived cell responses to Mls locus determinants: evidence that the Mls a allele is identical to the Mls d allele. J. Supramol. Struct. 8: 275. (oral) .

Molnar-Kimber, K., Jarocki-Witek, V., Dheer, S.K., Conley, A.J., Davis, A.R. and Hung, P.P. (1987). Evidence for regulation of expression of Hepatitis B envelope proteins by X open reading frame in recombinant Adenoviruses. Hepatitis B Viruses, Cold Spring Harbor Laboratories. Cold Spring Harbor, N.Y. p. 48. (oral)

Molnar-Kimber, K.L, Haigwood, N.L., Najarian, R., Jarocki-Witek, V., Dheer, S.K., Stauffer, B., Mizutani, S., Conley, A.J., Davis, A.R., and Hung, P.P. (1988). Characterization of the adenovirus-4 E3 region for the development of live recombinant vaccines. Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor Laboratories, Cold Spring Harbor, New York. p. 27. (oral)

Molnar-Kimber, K.L., Rhoad, A., Warner, L., Chen, H., Caggiano, T., Steffan, R. and Sehgal, S.N. (1994). Evidence that the anti-tumor and immunosuppressive effects of rapamycin are mediated via similar mechanisms. Cold Spring Harbor Symposium, p. 141.

Molnar-Kimber, K.L. (1995) "Mechanism of Rapamycin", International Congress on New Immunosuppressive Drugs. International Society of Transplant Surgeons, p.71.

Molnar-Kimber, K. L., Sterman, D.H., Elshami, A.,Kucharchuk, J., Amin, K., Roberts, J.R., Treat, J., Wilson, J., Kaiser, L. R., Albelda, S.M. (1996) The Human Immune Response to Adenoviral-based Gene Therapy for Localized Mesothelioma. Conference on Gene Therapy. TIGR Science Education Foundation, Inc., p. 60.

Molnar-Kimber, K.L., Sterman, D.H., Chang, M., Elshami, A., Roberts, J.R., Treat, J., Wilson, J., Kaiser, L. R., Albelda, S.M. (1996) Adenoviral based Gene Therapy for Patients with Localized Mesothelioma induced cellular and humoral immune responses. Fourth International Mesothelioma Conference, Philadelpia, PA GT3

Kang, E., Sterman, D., Chang, M., Gelfand, K., Albelda, S.M., Kaiser, L.R., and Molnar-Kimber, K.L. (1996). Lack of correlation between stage of mesothelioma and ability to mount an immune response. Fourth International Mesothelioma Conference, Philadelphia, PA I3.

Molnar-Kimber, K.L., Gelfand, K., Kang, E., Kaiser, L.R., Albelda, S.M. (1997) Administration of recombinant adenoviral based gene therapy intrapleurally induced a TH1 cellular immune response in mesothelioma patients. Sixth International Conference on Gene Therapy of Cancer 4 (6), O-36. oral

Toyoizumi, T., Abbas, AE, Kang, EH, Caparrelli, DJ, Albelda, SM, Kaiser, LR, Molnar-Kimber, KL. Mitomycin C augments oncolytic effect of Herpes simplex virus type I 34.5 mutants in model of non small cell lung cancer. Seventh International Conference on Cancer Gene Therapy 5 (6), (oral).

Coukos, G., Caparrelli, D.J., Makrigiannakis, A., Abbas, A.E., Kaiser, L.R., Rubin, S.C., Albelda, S.M., and K. L. Molnar-Kimber. Producer cells enhance the oncolytic activity of a replication-selective herpes simplex virus-1 mutant in Epithelial Ovarian cancer. Seventh International Conference on Cancer Gene Therapy 5 (6), (oral).

Caparrelli, D.J., Abbas, A.E., Toyoizumi, T., Lambright, E., Wernsing, D., Molnar-Kimber, K.L., and Kaiser, L.R. Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system. Society of Thoracic Surgeons, oral

Blank, S.V., Rubin, S.C., Albelda, S.M. and Molnar-Kimber, K.L. 1999. Combination therapy of human cervical cancer with radiation plus replication-competent herpes simplex virus-1 mutants. Second Annual Am.Soc. Gene Therapy Meeting.

Molnar-Kimber, K.L., Kang, E.H. , Gelfand, K., Abbas, A.E., Sterman, D., Albelda, S.M., Kaiser, L.R., 1999. Humoral anti-tumor immune response induced in mesothelioma patients by intrapleural administration of recombinant adenoviral-based gene therapy. Second Annual Am.Soc. Gene Therapy Meeting (oral).

Toyoizumi, T., Tsukuda, K., Sandhu, A. K., Odaka, M., Albelda, S. M., Amin, K., Kaiser, L.R., and Molnar-Kimber, K.L. (2000) CEA-Regulated Replication-Selective Adenovirus for Treatment of CEA-Positive Tumors Third Annual Am.Soc. Gene Therapy Meeting. A413.

Tsukuda, K., Toyoizumi, T., Sandu, A., Odaka, M., Albelda, S.M., Amin, K., Kaiser, L.R, and Molnar-Kimber, K.L. A CEA regulated Replication Selective Adenovirus is an Effective Oncolytic Agent for CEA+ Non Small Cell Lung Cancer. AACR A4649 (oral).

Toyoizumi, T., Tsukuda, K., Banet, G., Sandhu, A.K., Odaka, M., Albelda, S.M., Amin, A., Kaiser, L.R. and Molnar-Kimber, K.L. (2001). Deletion of E1A promoter elements enhances specificity of CEA-Driven Oncolytic Adenoviruses. Fourth Annual Am. Soc. Gene Therapy Meeting.

Blank, S.V., Rubin, S.C., Coukos, G., Amin, K.M., Albelda, S.M. and Molnar-Kimber, K.L. (2001). Replication selective Herpes Simplex Virus-1 mutant therapy of cervical cancer is enhanced by Low dose radiation. International Conference on Cancer Gene Therapy.

Molnar-Kimber, K.L., Miller, C. G., Hankey, A.H. IL-12 secretion augmented efficacy of oncolytic HSV mutants in immunocompetent peritoneal tumor model. ASGT, 2002.

Molnar-Kimber, K.L., Liu, R., Hankey, A.H. Oncolytic HSV Mutants for Treatment of Gynecologic Cancers. Banff Conference on Oncolytic Viruses, 2003. (Invited speaker)

Lively, experienced speaker for Arthritis

I’m a speaker who has first hand experience and thus relates to the audience quickly.

As a scientist with RA, I also understand the molecular, cellular and tissue biology of RA.

If you’re looking for a lively speaker on arthritis, please fill in the convenient contact page or call me at 610-990-7713.